Mifepristone

Major

Mifepristone Doxorubicin Adriamycin Increased DOXOrubicin exposure and an increased risk of DOXOrubicin-related adverse reactions Details Mifepristone Elacestrant Orserdu Increased CYP3A4 substrate exposure Details Mifepristone Encorafenib Braftovi Increased encorafenib exposure, reduced miFEPRIStone exposure and an increased risk of QT interval prolongation Details Mifepristone Eravacycline Injection Xerava Increased CYP3A4 substrate exposure Details Mifepristone Erdafitinib Balversa Increased erdafitinib exposure and an increased miFEPRIStone exposure Details Mifepristone Eribulin Injection Halaven An increased risk of QT interval prolongation Details Mifepristone Esketamine Nasal Spray Spravato Increased miFEPRIStone exposure Details Mifepristone Esomeprazole Nexium Increased miFEPRIStone exposure Details Mifepristone Esomeprazole Injection Nexium Increased miFEPRIStone exposure Details Mifepristone Estradiol Delestrogen Reduced hormonal contraceptive exposure, an increased miFEPRIStone exposure and an increased hormonal contraceptives exposure Details Mifepristone Estradiol Topical Divigel Reduced hormonal contraceptive exposure, an increased miFEPRIStone exposure and an increased hormonal contraceptives exposure Details Mifepristone Estradiol Transdermal Patch Alora® Reduced hormonal contraceptive exposure, an increased miFEPRIStone exposure and an increased hormonal contraceptives exposure Details Mifepristone Famotidine Calmicid An increased risk of QT interval prolongation Details Mifepristone Famotidine Injection Calmicid An increased risk of QT interval prolongation Details Mifepristone Felbamate Felbatol An increased risk of QT interval prolongation Details Mifepristone Felodipine Plendil® Increased CYP3A4 substrate exposure Details Mifepristone Flecainide Tambocor® An increased risk of QT interval prolongation Details Mifepristone Foscarnet Injection Foscavir Increased risk of QT interval prolongation Details Mifepristone Fostamatinib Tavalisse Increased CYP3A4 substrate exposure and an increased miFEPRIStone exposure Details Mifepristone Fostemsavir Rukobia Increased risk of torsade de pointes Details Mifepristone Futibatinib Lytgobi Increased CYP3A4 substrate exposure Details Mifepristone Galantamine Razadyne An increased risk of QT interval prolongation Details Mifepristone Gatifloxacin Ophthalmic Zymar® An increased risk of QT interval prolongation Details Mifepristone Gemifloxacin Factive An increased risk of QT interval prolongation Details Mifepristone Gilteritinib Xospata Increased CYP3A4 substrate exposure Details Mifepristone Glasdegib Daurismo Increased glasdegib exposure and an increased risk of QT interval prolongation Details Mifepristone Goserelin Implant Zoladex Increased risk of QT interval prolongation Details Mifepristone Granisetron Transdermal Patch Sancuso An increased risk of QT interval prolongation Details Mifepristone Granisetron Injection Granisol An increased risk of QT interval prolongation Details Mifepristone Guanfacine Intuniv Increased CYP3A4 substrate exposure Details Mifepristone Histrelin Implant Supprelin Increased risk of QT interval prolongation Details Mifepristone Hydroxychloroquine Plaquenil Increased risk of QT interval prolongation Details Mifepristone Ibrexafungerp Brexafemme Increased CYP3A4 substrate exposure and an increased miFEPRIStone exposure Details Mifepristone Ibrutinib Imbruvica Increased CYP3A4 substrate exposure Details Mifepristone Ifosfamide Injection Ifex Decreased ifosfamide effectiveness Details Mifepristone Infigratinib Truseltiq Increased CYP3A4 substrate exposure Details Mifepristone Inotuzumab Ozogamicin Injection Besponsa Increased risk of QT interval prolongation Details Mifepristone Irinotecan Camptosar Increased irinotecan exposure and an increased irinotecan active metabolite exposure Details Mifepristone Irinotecan Injection Camptosar Increased irinotecan exposure and an increased irinotecan active metabolite exposure Details Mifepristone Irinotecan Lipid Complex Injection Onivyde® Increased irinotecan liposome exposure and an increased irinotecan liposome active metabolite exposure Details